The USA has approved an HIV injection with almost 100% protection: only two injections a year.

The USA has approved a new method for HIV prevention that provides almost 100% protection. The American FDA has granted permission for the use of a new drug that only needs to be administered twice a year, with effectiveness practically at 100%.

Revolutionary drug for HIV prevention

The new drug Lenacapavir, developed by Gilead Sciences and branded as Yeztugo, has shown remarkable results after two decades of development. Studies conducted have shown that over 99.9% of people who received injections every six months remained uninfected with HIV.

Availability and challenges of the new drug

Experts believe that the ease of use of the new method - just two injections a year - could revolutionize the fight against the spread of HIV infection.

'We are on the brink of achieving the best form of prevention in the entire history of HIV,' noted AVAC executive director Mitchell Warren.

Despite the positive decision regarding the new drug, questions arise about its distribution in low-income countries, as funding for drug supply programs is already being cut. There is a question about how to organize the distribution of the drug in such regions. The USA has approved a new drug for HIV prevention that allows for nearly zero risk of infection. The new method could become a true revolution in HIV prevention, but questions about the drug's availability in low-income countries remain open.